China Medical System Holdings Limited: Proposed Secondary Listing on the Singapore Exchange

Core Viewpoint - The Company is proposing a secondary listing of its ordinary shares on the Singapore Exchange, which aims to attract funds focused on Asia-Pacific investments and enhance its business development in Southeast Asia and the Middle East [1][3]. Group 1: Proposed Secondary Listing - The Company has submitted a confidential application for the proposed secondary listing on the SGX-ST and is awaiting the eligibility-to-list letter from the SGX-ST [2][5]. - The proposed secondary listing will not involve the issuance of new shares, and the shares will continue to be primarily listed on the Hong Kong Stock Exchange [1]. Group 2: Business Development and Strategy - The Company aims to optimize its shareholder structure and enhance its global reputation and market position through the proposed secondary listing [3]. - Singapore has been established as the regional headquarters for the Company's Southeast Asia and Middle East business, covering the entire pharmaceutical value chain [3]. - The Company operates several subsidiaries in Singapore, including CMS R&D, PharmaGend, Rxilient, and Singapore Venture Capital, to provide high-quality treatment options and contribute to the pharmaceutical industry in Southeast Asia [3]. Group 3: Market Position and Focus - The Company focuses on global first-in-class (FIC) and best-in-class (BIC) innovative products, promoting clinical research and commercialization to benefit patients [7]. - The Company has developed proven commercialization capabilities and extensive networks in specialty therapeutic fields, aiming to strengthen its market position in cardio-cerebrovascular, gastroenterology, skin health, and ophthalmology businesses [8]. - The Company is striving to become a "bridgehead" for global pharmaceutical companies entering the Southeast Asian market, supporting sustainable development [8].